PRODUCT SUMMARY
Natural Ingredients - No
Suitable for men and women - MEN ONLY
Suitable for balding crowns - Yes
Suitable for pattern hair loss - Yes
Suitable for receding hairlines - Yes
Suitable for Alopecia Areata - No
Oral product - Yes
Topical product - No
Shampoo available - No
Conditioner available - No
Main ingredient - Dutasteride
Typical cost for 1 mth supply - $55 - 125
Average time to see results - 6-12 months
Recommended supplier - Please refer to your physician
WHAT IS AVODART?
Dutasteride is indicated for the treatment of symptomatic benign prostatic
hyperplasia (BPH) in men with an enlarged prostate to improve urinary
symptoms, reduce risk of acute urinary retention (AUR) and reduce
the risk of the need for BPH-related surgery.
As a second-generation 5 alpha-reductase inhibitor (5
A-RI), it is the first and only medicine to inhibit both the type
1 and type 2 enzymes responsible for the conversion of testosterone
to DHT (dihydrotestosterone), the primary cause of prostate growth.
Its dual inhibition decreases levels of DHT by 90 percent at two
weeks and 93 percent at two years. By reducing DHT levels, Avodart
reduces the size of an enlarged prostate.
HOW DOES IT WORK?
BPH is one of the most common health problems in older
men. BPH is a progressive condition in which the prostate gland
surrounding the urethra enlarges. As it grows, the enlarged prostate
obstructs the urethra, the tube through which urine flows, causing
urinary difficulties. An enlarged prostate can continue to increase
in size and in severe cases lead to acute urinary retention (AUR;
a sudden and complete inability to urinate) and the need for BPH-related
surgery.
DHT (dihydrotestosterone) is the male hormone primarily
responsible for the initial development and subsequent enlargement
of the prostate gland. Avodart, a second-generation 5 alpha-reductase
inhibitor, is the first and only medicine to inhibit both the type
1 and type 2 enzymes responsible for the conversion of the male
hormone testosterone to DHT.
Its dual inhibition decreases levels of DHT by 90 percent
at two weeks and 93 percent at two years. By reducing DHT levels,
Avodart reduces the size of an enlarged prostate.
It also improves urinary symptoms and reduces the risk
of AUR and the need for BPH-related surgery, two potential long-term
serious consequences of BPH.
CLINICAL TESTS
Dutasteride was investigated in three large, well-controlled
multi-center studies involving 4,325 men aged 50 and above with
a serum PSA level = 1.5 ng/mL and < 10 ng/mL, and BPH diagnosed
by medical history and physical examination, including enlarged
prostate (greater than or equal to 30 cc) and BPH symptoms that
were moderate to severe according to the American Urological Association
Symptom Index.
Data from these two-year clinical trials demonstrated
that treatment with the drug(0.5 mg once daily) reduced the risk
of both AUR and BPH-related surgical intervention relative to placebo,
improved BPH-related symptoms, decreased prostate volume, and increased
maximum urinary flow rates.
SIDE EFFECTS
Clinical trials showed that it was generally well tolerated.
Most side effects were mild or moderate and generally went away
while on treatment in both the Avodart and placebo groups.
Drug-related side effects during the first six months
were as follows: impotence (4.7 percent vs. 1.7 percent for placebo),
decreased libido (3 percent vs. 1.4 percent), breast tenderness
and breast enlargement (gynecomastia; 0.5 percent vs. 0.2 percent)
and ejaculation disorders (1.4 percent vs. 0.5 percent).
The incidence of most drug-related sexual side effects
decreased with duration of treatment. The incidence of drug-related
breast tenderness and breast enlargement remained constant over
the treatment period. Ejaculate volume may be decreased in some
patients with continued treatment. This decrease did not appear
to interfere with normal sexual function.
IMPORTANT INFORMATION
This drug should not be used in women and children.
Women who are pregnant or may become pregnant should not handle
Avodart because of possibility of absorption of active chemicals
and subsequent potential risk to a male fetus.
Men treated with Avodart should not donate blood until
at least six months after their final dose to prevent giving Avodart
to a pregnant woman through a blood transfusion.
Men with an allergic reaction to this medication or
its ingredients should not take it.
Men with liver disease should talk to their doctor before
taking Avodart.
Avodart will reduce the amount of PSA measured in the
blood. A physician will be aware of this effect and can still use
PSA to detect prostate cancer.
Although improvement in urinary symptoms was seen in
some patients by three months, a therapeutic trial of at least six
months is usually necessary to assess whether a beneficial response
in symptom relief is achieved with Avodart.
Dosing - The recommended dose of Avodart is a 0.5 mg soft gelatin
capsule taken once daily.
Indication - This medication is indicated for the treatment
of symptomatic benign prostatic hyperplasia (BPH) in men with an
enlarged prostate to improve urinary symptoms, reduce risk of acute
urinary retention and reduce the risk of the need for BPH-related
surgery.
You can find out more about this medication by visiting
the manufacturer's site at Avodart.com
THIS DRUG HAS NOT YET BEEN APPROVED FOR THE TREATMENT OF HAIR LOSS
AND YOU MAY HAVE DIFFICULTY IN PERSUADING YOUR PHYSICIAN TO PRESCRIBE
THE DRUG FOR THIS CONDITION.
Return
to Hair Loss Treatments
New Hair Loss Treatmanet - eBook |
 |
 |
Hair Loss
Conquered
"Finally, you can find out the real way to
end going bald for good. Stop wasting your money
on expensive medications and over-the-counter products
- this step-by-step program reveals how to stop
your hair loss and even regrow the hair you thought
you had lost forever, in just a few minutes a day!"
From the Desk of Chris T. Oxford
» Learn
More |
|
 |
|
Natural Hair Loss Treatment - eBook |
|
|